StoxNeuland Laboratories vs Granules India: share price & financials comparison
NSE: NEULANDLAB vs GRANULES · Healthcare · as of 06 Nov 2026
Both prices rebased to 100 at the start of the selected period.
Neuland Laboratories vs Granules India at a glance
Neuland Laboratories (NEULANDLAB) has a market capitalisation of ₹25,414 Cr, against ₹21,813 Cr for Granules India (GRANULES). Over the past year Granules India has returned +40.0%, compared with +27.9% for Neuland Laboratories. On valuation, Granules India trades at a lower P/E of 30.6 versus 56.2. Neuland Laboratories earns a higher return on equity (22.3% vs 10.9%). Neuland Laboratories comes out ahead on profitability and technicals. Granules India comes out ahead on size, valuation and financial health. Across the scored metrics below, Neuland Laboratories leads on 8 and Granules India on 9. On StoxGud's 10-point checklist, Neuland Laboratories scores 7/10 and Granules India scores 8/10.
| Metric | Neuland Laboratories | Granules India |
|---|---|---|
| Size | ||
| Market cap | ₹25,414 Cr | ₹21,813 Cr |
| Revenue (latest FY) | ₹2,023 Cr | ₹5,366 Cr |
| Net profit (latest FY) | ₹364 Cr | ₹595 Cr |
| Valuation | ||
| P/E | 56.2 | 30.6 |
| P/B | 12.52 | 3.32 |
| Dividend yield | 0.06% | 0.17% |
| Profitability | ||
| Return on equity | 22.3% | 10.9% |
| Net profit margin | 19.6% | 12.1% |
| Operating margin | 30.6% | 22.7% |
| Growth | ||
| Revenue growth (YoY) | -12.6% | +20.3% |
| Net profit growth (YoY) | — | +39.2% |
| Revenue CAGR (multi-year) | +16.6% | +10.6% |
| Financial health | ||
| Debt to equity | 0.17 | 0.09 |
| Momentum | ||
| 1-month return | -9.0% | -5.4% |
| 1-year return | +27.9% | +40.0% |
| 3-year CAGR | +69.6% | +31.6% |
| 5-year CAGR | +64.0% | +20.2% |
| 10-year CAGR | +34.4% | +21.4% |
| Distance from 52W high | -17.9% | -12.1% |
| Technicals | ||
| RSI (14) | 50 | 42 |
| Price vs 200-day avg | +12.4% | +7.5% |
Highlighted cells lead on that metric. Market cap, revenue and RSI are shown for context and not scored.
10-point checklist side by side
| Check | Neuland Laboratories | Granules India |
|---|---|---|
| Price above 50-day average | ✗ | ✗ |
| Price above 200-day average | ✓ | ✓ |
| 50-day average above 200-day (uptrend) | ✓ | ✓ |
| RSI in healthy 40–70 zone | ✓ | ✓ |
| Positive 1-year return | ✓ | ✓ |
| Return on equity above 15% | ✓ | ✗ |
| Debt to equity below 1 | ✓ | ✓ |
| Revenue growing year on year | ✗ | ✓ |
| Net profit margin above 10% | ✓ | ✓ |
| P/E below industry median | ✗ | ✓ |
| Score | 7/10 | 8/10 |
A rules-based screen for education only — not a buy or sell recommendation.
FAQs
Which is bigger, Neuland Laboratories or Granules India?
Neuland Laboratories has a market cap of ₹25,414 Cr and Granules India has a market cap of ₹21,813 Cr as of 06 Nov 2026.
Which has a lower P/E, Neuland Laboratories or Granules India?
Granules India has the lower P/E: Neuland Laboratories trades at 56.2 and Granules India at 30.6.
Which gave better returns in the last year, Neuland Laboratories or Granules India?
Granules India did better: Neuland Laboratories returned +27.9% and Granules India returned +40.0% over one year.
Is Neuland Laboratories or Granules India a better buy?
StoxGud does not give buy or sell recommendations. On our rules-based checklist Neuland Laboratories scores 7/10 and Granules India scores 8/10; compare valuation, profitability, growth and momentum above and consult a SEBI-registered adviser.